ריספרדל 3 מג Izrael - hebrejski - Ministry of Health

ריספרדל 3 מג

j-c health care ltd - risperidone - טבליות מצופות פילם - risperidone 3 mg - risperidone - risperidone - risperdal is indicated for the management of schizophrenia and manifestation of psychotic disorders. the antipsychotic efficacy of risperdal was established in short-term (6 to 8-weeks) controlled trials of schizophrenic inpatients. risperdal is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.risperdal is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. conduct and other disruptive disorders: treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment-requiring behavioral disorders with reduced or substandard intelligence. treatment should not be given to children under the age of 5 years.risperdal is indicated for the treatment of mania in bipolar disorder. these episodes are char

איקסל 25 מג Izrael - hebrejski - Ministry of Health

איקסל 25 מג

perrigo israel agencies ltd - milnacipran hydrochloride - קפסולות - milnacipran hydrochloride 25 mg - milnacipran - milnacipran - treatment of major (i.e. all characteristics) depressive episodes in adults over 18 years old.

מיפלוניד אבקה לאינהלציה 200 מקגקפסולה Izrael - hebrejski - Ministry of Health

מיפלוניד אבקה לאינהלציה 200 מקגקפסולה

novartis israel ltd - budesonide - קפסולות - budesonide 200 mcg - budesonide - budesonide - maintenance treatment of bronchial asthma.

זולאייר   150 מג Izrael - hebrejski - Ministry of Health

זולאייר 150 מג

novartis israel ltd - omalizumab - אבקה וממס להכנת תמיסה להזרקה - omalizumab 150 mg/dose - omalizumab - omalizumab - xolair is indicated for adults and adolescents (12 years of age and above) with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. xolair has been shown to decrease the incidence of asthma exacerbations in these patients. safety and efficacy have not been established in other allergic conditions.

מווקס תמיסה Izrael - hebrejski - Ministry of Health

מווקס תמיסה

vitamed pharmaceutical industries ltd - bromhexine hydrochloride - תמיסה - bromhexine hydrochloride 2.00 mg/ml - bromhexine - bromhexine - bronchial mucolytic. it can also be given by inhalation as an aerosol solution.

טוסין Izrael - hebrejski - Ministry of Health

טוסין

padagis israel agencies ltd, israel - dextromethorphan hydrobromide; guaifenesin - סירופ - dextromethorphan hydrobromide 10 mg / 5 ml; guaifenesin 100 mg / 5 ml - dextromethorphan - dextromethorphan - for relief of cough and expecctorant.

טוסין Izrael - hebrejski - Ministry of Health

טוסין

padagis israel agencies ltd, israel - dextromethorphan hydrobromide; guaifenesin - סירופ - dextromethorphan hydrobromide 10 mg / 5 ml; guaifenesin 100 mg / 5 ml - dextromethorphan - dextromethorphan - for relief of cough and expecctorant.

קאפקס Izrael - hebrejski - Ministry of Health

קאפקס

padagis israel agencies ltd, israel - dextromethorphan hydrobromide; guaifenesin - סירופ - dextromethorphan hydrobromide 10 mg / 5 ml; guaifenesin 100 mg / 5 ml - dextromethorphan - dextromethorphan - for relief of cough and expecctorant.

קאפקס Izrael - hebrejski - Ministry of Health

קאפקס

padagis israel agencies ltd, israel - dextromethorphan hydrobromide; guaifenesin - סירופ - dextromethorphan hydrobromide 10 mg / 5 ml; guaifenesin 100 mg / 5 ml - dextromethorphan - dextromethorphan - for relief of cough and expecctorant.

נבנק Izrael - hebrejski - Ministry of Health

נבנק

novartis israel ltd - nepafenac - תרחיף לעין - nepafenac 0.1 % - nepafenac - nepafenac - prevention and treatment of postoperative pain and inflammation associated with cataract surgery and reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.